Alkermes Plc
ALKS28.520USD
+0.030+0.11%
終値 12/24, 16:00（ET）15分遅れの株価
4.71B時価総額
13.82直近12ヶ月PER
詳細情報 Alkermes Plc 企業名
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Alkermes Plcの企業情報
企業コードALKS
会社名Alkermes Plc
上場日Jul 16, 1991
最高経営責任者「CEO」Pops (Richard F)
従業員数1800
証券種類Ordinary Share
決算期末Jul 16
本社所在地Connaught House
都市DUBLIN
証券取引所NASDAQ OMX - NASDAQ BASIC
国Ireland
郵便番号D04 C5Y6
電話番号35317728000
ウェブサイトhttps://www.alkermes.com/
企業コードALKS
上場日Jul 16, 1991
最高経営責任者「CEO」Pops (Richard F)
Alkermes Plcの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.29M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
205.37K
+0.55%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
103.74K
+3.84%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
65.74K
-5.74%
Mr. Brian P. Mckeon
Mr. Brian P. Mckeon
Independent Director
Independent Director
43.87K
+16.12%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
31.08K
+24.36%
Dr. Cato T. Laurencin, M.D., Ph.D.
Dr. Cato T. Laurencin, M.D., Ph.D.
Independent Director
Independent Director
29.10K
+26.46%
Dr. Christopher I. Wright, M.D., Ph.D.
Dr. Christopher I. Wright, M.D., Ph.D.
Independent Director
Independent Director
23.01K
+12.23%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Independent Director
Independent Director
10.71K
+131.91%
Dr. Nancy L. Snyderman, M.D.
Dr. Nancy L. Snyderman, M.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.29M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
205.37K
+0.55%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
103.74K
+3.84%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
65.74K
-5.74%
Mr. Brian P. Mckeon
Mr. Brian P. Mckeon
Independent Director
Independent Director
43.87K
+16.12%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
31.08K
+24.36%
収益内訳
通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
VIVITROL
121.66M
31.14%
ARISTADA
101.30M
25.93%
LYBALVI
84.28M
21.57%
Royalty Revenue - VUMERITY
32.02M
8.20%
Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA
30.32M
7.76%
他の
21.09M
5.40%
会社から関連データがまだ開示されていません。
事業別
地域別
事業別USD
会社名
収益
比率
VIVITROL
121.66M
31.14%
ARISTADA
101.30M
25.93%
LYBALVI
84.28M
21.57%
Royalty Revenue - VUMERITY
32.02M
8.20%
Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA
30.32M
7.76%
他の
21.09M
5.40%
株主
更新時刻: Mon, Nov 17
更新時刻: Mon, Nov 17
株主統計
種類
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
14.33%
The Vanguard Group, Inc.
10.98%
T. Rowe Price Associates, Inc.
6.09%
State Street Investment Management (US)
5.17%
Baker Bros. Advisors LP
4.90%
他の
58.54%
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
14.33%
The Vanguard Group, Inc.
10.98%
T. Rowe Price Associates, Inc.
6.09%
State Street Investment Management (US)
5.17%
Baker Bros. Advisors LP
4.90%
他の
58.54%
種類
株主統計
比率
Investment Advisor
54.03%
Investment Advisor/Hedge Fund
28.01%
Hedge Fund
17.63%
Pension Fund
2.30%
Research Firm
2.18%
Individual Investor
1.48%
Sovereign Wealth Fund
1.18%
Bank and Trust
0.44%
Private Equity
0.42%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
744
175.23M
117.54%
-23.12K
2025Q3
767
175.30M
122.16%
+2.11M
2025Q2
769
173.38M
125.62%
-4.15M
2025Q1
759
177.46M
124.05%
-27.05M
2024Q4
734
172.08M
130.58%
-12.03M
2024Q3
705
184.36M
134.23%
-884.11K
2024Q2
687
185.17M
126.42%
+3.87M
2024Q1
659
181.61M
124.10%
-28.36M
2023Q4
633
182.01M
111.83%
+12.84M
2023Q3
601
169.31M
104.05%
+9.33M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
BlackRock Institutional Trust Company, N.A.
23.73M
14.37%
-251.67K
-1.05%
Jun 30, 2025
The Vanguard Group, Inc.
18.45M
11.18%
+290.40K
+1.60%
Jun 30, 2025
T. Rowe Price Associates, Inc.
9.86M
5.97%
-1.76M
-15.13%
Jun 30, 2025
State Street Investment Management (US)
8.21M
4.97%
+185.59K
+2.31%
Jun 30, 2025
Baker Bros. Advisors LP
6.41M
3.88%
+1.93M
+42.99%
Jun 30, 2025
Renaissance Technologies LLC
5.81M
3.52%
+71.33K
+1.24%
Jun 30, 2025
American Century Investment Management, Inc.
3.66M
2.22%
+191.55K
+5.53%
Jun 30, 2025
Geode Capital Management, L.L.C.
4.02M
2.44%
+83.86K
+2.13%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
3.10M
1.88%
+105.63K
+3.53%
Jun 30, 2025
JP Morgan Asset Management
3.95M
2.39%
-179.85K
-4.36%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
AdvisorShares Psychedelics ETF
7.31%
iShares Neuroscience and Healthcare ETF
3.82%
First Trust NYSE Arca Biotechnology Index Fund
3.3%
Invesco S&P SmallCap Health Care ETF
3.1%
ALPS Medical Breakthroughs ETF
2.07%
Knowledge Leaders Developed World ETF
1.69%
Langar Global HealthTech ETF
1.44%
State Street SPDR S&P Biotech ETF
1.35%
Abacus FCF International Leaders ETF
1.34%
Invesco S&P SmallCap Quality ETF
1.32%
詳細を見る
AdvisorShares Psychedelics ETF
比率7.31%
iShares Neuroscience and Healthcare ETF
比率3.82%
First Trust NYSE Arca Biotechnology Index Fund
比率3.3%
Invesco S&P SmallCap Health Care ETF
比率3.1%
ALPS Medical Breakthroughs ETF
比率2.07%
Knowledge Leaders Developed World ETF
比率1.69%
Langar Global HealthTech ETF
比率1.44%
State Street SPDR S&P Biotech ETF
比率1.35%
Abacus FCF International Leaders ETF
比率1.34%
Invesco S&P SmallCap Quality ETF
比率1.32%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
よくある質問
Alkermes Plcの上位5名の株主は誰ですか？
Alkermes Plcの上位5名の株主は以下のとおりです。
BlackRock Institutional Trust Company, N.A.は23.73M株を保有しており、これは全体の14.37%に相当します。
The Vanguard Group, Inc.は18.45M株を保有しており、これは全体の11.18%に相当します。
T. Rowe Price Associates, Inc.は9.86M株を保有しており、これは全体の5.97%に相当します。
State Street Investment Management (US)は8.21M株を保有しており、これは全体の4.97%に相当します。
Baker Bros. Advisors LPは6.41M株を保有しており、これは全体の3.88%に相当します。
BlackRock Institutional Trust Company, N.A.は23.73M株を保有しており、これは全体の14.37%に相当します。
The Vanguard Group, Inc.は18.45M株を保有しており、これは全体の11.18%に相当します。
T. Rowe Price Associates, Inc.は9.86M株を保有しており、これは全体の5.97%に相当します。
State Street Investment Management (US)は8.21M株を保有しており、これは全体の4.97%に相当します。
Baker Bros. Advisors LPは6.41M株を保有しており、これは全体の3.88%に相当します。
Alkermes Plcの株主タイプ上位3種は何ですか？
Alkermes Plcの株主タイプ上位3種は、
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
T. Rowe Price Associates, Inc.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
T. Rowe Price Associates, Inc.
Alkermes Plc（ALKS）の株式を保有している機関の数はいくつですか？
2025Q4時点で、Alkermes Plcの株式を保有している機関は744社あり、保有株式の総市場価値は約175.23Mで、全体の117.54%を占めています。2025Q3と比較して、機関の持ち株は-4.62%増加しています。
Alkermes Plcの最大の収益源は何ですか？
FY2025Q2において、VIVITROL部門がAlkermes Plcにとって最大の収益を生み出しており、その金額は121.66Mで、全収益の31.14%を占めています。
